21-hydroxylase deficiency: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Usama Talib (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
'''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | ||
{{21- | {{21-Hydroxylase Deficiency}} | ||
{{CMG}} {{MJ}} | {{CMG}} {{MJ}} | ||
Revision as of 19:39, 19 July 2017
For patient information click here
Template:21-Hydroxylase Deficiency
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Mehrian Jafarizade, M.D [2]
Synonyms and keywords: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency; 21-hydroxylase deficiency; 21-hydroxylase deficient congenital adrenal hyperplasia; CAH1; CYP21A deficiency; Congenital adrenal hyperplasia 1
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters